Introduction
============

Parkinson's disease (PD) is a common neurodegenerative disorder affecting approximately 1% of people over the age of 60 of the world and 1.7% of people over 65 in China ([@B30]; [@B5]). Clinically, PD is manifested by classical motor symptoms, including tremor, rigidity, bradykinesia, and postural instability ([@B14]). Increasing evidence has suggested that PD is probably caused by a combination of genetic and environmental risk factors ([@B14]). During the past 20 years, more than 20 locis and 9 genes have been found associated with PD ([@B15]). One such gene, PARK 7/DJ-1 aroused our interest since it played an important role in both familial and sporadic PD.

The human DJ-l gene is located on 1p36.23. DJ-1 protein acts as a molecular chaperone which plays a protective role in oxidative stress ([@B3]). Loss of function mutations in the DJ-1 gene, including deletion of exon 1-5 ([@B2]), L166P ([@B2]), R98Q ([@B1]; [@B11]), M26I ([@B1]), E64D ([@B12]), and L172Q ([@B24]), have been demonstrated to cause degeneration of dopamine neurons and autosomal recessive inherited PD. However, these causative mutations explained less than 10% of PD patients since about 90% of cases are sporadic without these mutations ([@B23]). Shen's group examined DJ-1 protein levels in SNc of 18 sporadic PD cases and found a lower level than that of normal control group ([@B19]). Similarly, lower DJ-1 protein level was also observed in cerebrospinal fluid (CSF) of sporadic PD patients compared with normal controls ([@B13]). These findings strongly indicated that a low level of DJ-1 might contribute to the pathogenesis of sporadic PD. The observation in our previous research that knockdown (KD) DJ-1 could increase MPP+ induced ROS production and cell death further supported the above hypothesis ([@B28]). However, the mechanism of low DJ-1 protein level in sporadic PD is still obscure.

Since DJ-1 gene mutations are rarely found in sporadic PD, we hypothesized that low DJ-1 protein levels in sporadic PD might be related to dysregulation of gene expression. The transcriptional initiation is the basic step of gene expression, and the promoter is the most fundamental element to initiate transcription. Polymorphic sites in the promoter may affect the binding and regulatory ability of transcription factors (TFs) to the promoter and influence transcriptional activity. Whether polymorphisms in the DJ-1 promoter affect the transcriptional activity and relate to the occurrence of PD is unknown. The promoter of DJ-1 is believed in a 2.1 kB area (-1015∼+1104) across the Transcription Start Site (TSS) ([@B25]). [@B25] discovered a significant regulatory region in the promoter present at -109 to -101 from the TSS, and [@B7] showed a region located at -78 to -73 from the TSS ([Figure 1](#F1){ref-type="fig"}), which could dramatically upregulate the expression of DJ-1. Considering that polymorphisms present at or near these regions might affect promoter activity and lead to low DJ-1 protein levels, we sequenced an area containing the above regions of DJ-1 promoter (NC_000001.11: 7961201-7962000) in 523 sporadic PD patients and 599 controls in Chinese Han population to screen the polymorphisms which may be associated with PD. To further analyze the genetic association, detected polymorphisms in the DJ-1 gene promoter region were looked up in existing public genome-wide association studies (GWAS) meta-analysis database PDGene. Meta-analysis of this study and previous reports was also conducted. Dual-luciferase assay was used to access the influences of detected polymorphisms on DJ-1 transcriptional activity. To further assess the association between detected polymorphisms and human brain DJ-1 expression level, expression quantitative trait loci (eQTL) analysis results were searched in GTEx Portal.

![Schematic view of relative positions of the polymorphisms investigated in the study. The first base of TSS was defined as 1, the first upstream base of TSS is --1, the relative positions of 4 polymorphisms observed in our cohort and previous reported functional sites (Sp-1 or XBP-1S binding site) were calculated based on TSS. The range of --500∼+300 across TSS (NC_000001.11: 7961201-7962000) containing the above functional areas of DJ-1 promoter was sequenced in the study. Representative sequence of rs17523802 G \> A heterozygote, rs226249 heterozygote, rs200968609 heterozygote, and rs35675666 homozygote were shown.](fnagi-11-00024-g001){#F1}

Materials and Methods {#s1}
=====================

Study Population
----------------

523 PD patients were recruited from movement disorders clinics in Ruijin Hospital, Shanghai, China. All patients were diagnosed with idiopathic PD by at least two movement disorders specialists according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria ([@B9]). 599 unrelated controls were recruited from communities of Shanghai in epidemiologic investigation program. Each of the control had no evidence of neurodegenerative disease. All participants were Chinese Han residing in Shanghai. Any participants with a family history of PD were excluded. Demographic information \[gender, age, age at onset, medication status, oral Levodopa Equivalent Dose (LED), disease duration, etc\] and peripheral blood samples were collected from participants. The modified Hoehn and Yahr scale (H-Y) was rated in the OFF state of each patient. LED was computed according to the protocol provided by [@B27]. Lifestyle factors including smoking and consumption of alcohol were also recorded. PD patients were divided into Tremor Dominant (TD), Akinetic/Rigid (AR) and Mixed (MX) subtypes by the criteria used in previous studies ([@B20]). TD: rest tremor as sustained dominant symptom over bradykinesia and rigidity; Akinetic/Rigid dominant (AR): predominantly bradykinetic motor features with no or only mild rest tremor; Mixed motor feature group (MX): rest tremor, bradykinesia and rigidity present at the time of diagnosis or sustained comparable severity of tremor and bradykinetic motor features. Patients with age at onset \<50 were classified as early-onset PD (EOPD), ≥50 years as late-onset PD (LOPD). The study was in accordance with the Helsinki Declaration of 1975. Written informed consents were obtained from all participants. Approval for the study was obtained from the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (2011-No. 13).

Blood Sample Collection and Genetic Analysis
--------------------------------------------

Peripheral blood samples were collected in EDTA anticoagulant tubes and placed immediately on ice. After the lysis of erythrocytes, blood samples were centrifuged at 3000 rpm for 10 min to isolate leukocytes. DNA was extracted from leukocytes through standardized phenol/chlorine extraction method. The range of -500∼+300 across TSS (NC_000001.11: 7961201--7962000) in DJ-1 promoter was amplified and sequenced (Schematic view of the area was shown in [Figure 1](#F1){ref-type="fig"}). The primers used for polymerase chain reaction (PCR) amplification were as follows: forward 5′-ACTGCTCTAGTCCTGTGGGT-3′ and reverse 5′-CAGCTCGCCTCATGAC-ATCT-3′. With the PrimeSTAR DNA Polymerase (Takara, Dalian, China), following an initial denaturation at 94°C for 5 min, 30 PCR cycles were performed according to a 68--50°C touchdown PCR protocol (the first 12 cycles: 98°C for 15 s, 68--50°C for 15 s, 72°C for 1 min 50 s, the annealing temperature decreases by 1.5°C every cycle from 68 to 50°C; the next 18 cycles: 98°C for 15 s, 50°C for 15 s, 72°C for 1 min 50 s) with a final extension at 72°C for 5 min. After PCR amplification, the product was electrophoresed in 1.5% agarose gels containing ethidium bromide, purified and directly sequenced (Biosune, Shanghai, China). Sequences were aligned to the reference human genome sequence (NC_000001.11) using the SnapGene software (from GSL Biotech, available at ^[1](#fn01){ref-type="fn"}^) and the Mutation Surveyor software (form SoftGenetics, available at ^[2](#fn02){ref-type="fn"}^).

Meta-Analysis of the Association Between DJ-1 Promoter Polymorphisms and PD
---------------------------------------------------------------------------

The four variations were looked up in GWAS meta-analysis database PDGene^[3](#fn03){ref-type="fn"}^. Meta-analysis *p*-values and odds ratios (OR) of the four variations based on 13,708 PD cases and 95,282 controls from 13 independent GWAS datasets of European descent were obtained ([@B17]). Due to privacy protection and data sharing restrictions, detailed genotype information of the four variations were not accessible. Thus, only Meta *p* values and Meta OR of the four variations in GWAS reports were listed in [Table 5](#T5){ref-type="table"}. Except for existing GWAS data, other related previous case-control studies were searched in PubMed, Embase and Web of Science, using the following terms "(polymorphism OR SNP) AND (DJ-1 OR PARK7) AND (PD OR Parkinson's disease)," "(rs17523802 OR rs226249 OR rs200968609 OR rs35675666) AND (PD OR Parkinson's disease)." Studies on irrelevant polymorphisms were eliminated, and finally, 6 independent case-control studies were selected. Genotype data were retrieved from the 6 studies and analyzed. Detailed information of the studies including race, minor allele frequencies (MAF) and sample counts were shown in [Table 6](#T6){ref-type="table"}. Meta-analysis was conducted with the Review Manager version 5.3.5 under the random effect model.

Construction of Luciferase Reporter Gene Vectors and Dual-Luciferase Reporter Assays
------------------------------------------------------------------------------------

The DJ-1 promoter plasmid, containing the T or C allele at rs226249, or the A or G allele at rs17523802 (since rs17523802, rs200968609 and rs35675666 showed strong linkage pattern with *r*^2^ = 1, three haplotypes were constructed: G-C-ins-G and G-T-ins-G to detect rs226249 function, G-C-ins-G and A-C-del-T to detect rs17523802, rs200968609 and rs35675666 function, alleles arrayed in order of rs17523802, rs226249, rs200968609 and rs35675666), were amplified from the genomic DNA of PD patients, using primers containing BglII in the forward primer and HindIII in the reverse primer for cloning (forward: 5′-GAAGATCTACTGCTCTAGTCCTGTGGGT-3′ and reverse: 5′-CCCAAGCTTCATTGCAACCCTGAGATACCCC-3′). PCR was performed: denatured at 94°C for 5 min, and amplified for 30 cycles at 98°C 15 s, 56°C 20 s, 72°C 1 min 45 s, with terminal extension at 72°C 5 min. After digested with Bgl II and HindIII (Takara, Dalian, China) and purified (Tiangen, Beijing, China), the fragments were cloned into the pGL3-basic luciferase plasmid (Promega, Beijing, China).

Human neuroblastoma cells (SH-SY5Y) were cultured in DMEM medium with 10% FBS (GIBCO/Invitrogen, Shanghai, China) and incubated at 37°C in a humidified environment with 5% CO2. SH-SY5Y cells were plated into 24-well culture plates 24 h prior to transfection, and cells were 80% confluent at transfection. 490 ng polymorphism plasmid or pGL3-basic empty plasmid (as a negative control) was transfected into SH-SY5Y cells using Lipofectamine 3000 (Invitrogen, Shanghai, China), with 10 ng Renilla pRL-TK plasmid (Promega, Beijing, China) cotransfected as a normalizing control. After 24 h, cells were rinsed with PBS and harvested with Passive Lysis buffer (Promega). Transcriptional activity was determined using the Dual-Luciferase Reporter Assay System (Promega, Beijing, China) on a Synergy^TM^ H4 Hybrid Microplate Reader (BioTek, Shanghai, China). For each plasmid construct, four independent transfection experiments were carried out and readings were taken in duplicate. The transcriptional activities were reported as relative luciferase activities, which was the ratio of firefly luciferase activities over renilla luciferase activities.

Analyzing the Effects of DJ-1 Promoter Polymorphisms on DJ-1 Gene Expression in Normal Human Brain
--------------------------------------------------------------------------------------------------

The potential impact of DJ-1 promoter SNPs on DJ-1 gene expression was evaluated by eQTL analysis. The data used for the analyses were obtained from the GTEx Portal^[4](#fn04){ref-type="fn"}^ and dbGaP (accession number [phs000424.vN.pN](phs000424.vN.pN)).

Statistical Analysis
--------------------

All statistical analysis was performed using the SPSS software. For analyzing demographic statistics, a Mann--Whitney *U*-test was used for continuous variables and a Chi-squared test or Fisher's exact test was used for nominal data. The Chi-squared test or Fisher's exact test was used to assess the deviation of alleles in (HWE) and to evaluate the differences in genotype and allele distributions between groups. Measures of linkage disequilibrium (D' and r2) were computed from participants' genotypes with Haploview 4.1 (from Broad Institute, available at ^[5](#fn05){ref-type="fn"}^). Each genotype was estimated by logistic regression analysis presuming additive mode of inheritance under correcting by confounders. A two-tailed *P* \< 0.05 was considered statistically significant. For multiple statistical tests, the Bonferroni method was applied to correct the alpha level and *P* values accordingly.

Results
=======

Demographic and Clinical Characteristics of Participants
--------------------------------------------------------

Characteristics of 1122 participants were shown in [Table 1](#T1){ref-type="table"}. No significant statistical difference was observed for age and gender between PD and controls (*P* \> 0.05). Compared to controls, PD patients were less likely to ever smoke cigarettes or drink alcohol (*P* \< 0.05) ([Table 1](#T1){ref-type="table"}), which is consistent with several studies ([@B18]; [@B29]). Gender, disease duration, Hoehn and Yahr stage and oral LED/day showed different distribution among three PD motor subtypes: There were more male patients in the AR group; Tremor Dominant (TD) group consisted of more early stage PD patients compared to AR and MX group. Between EOPD and LOPD subgroups, the distribution of age and age at onset was as expected ([Table 1](#T1){ref-type="table"}).

###### 

Demographic and clinical characteristics of controls and PD patients.

  Characteristics^a^          Controls *N* = 599   Total PD *N* = 523   *p*           Subtypes of PD defined by motor symptoms   Subtypes of PD defined by onset age                                                                       
  --------------------------- -------------------- -------------------- ------------- ------------------------------------------ ------------------------------------- ----------------- ------------- ----------------- ----------------- -------------
  Gender                                                                                                                                                                                                                                   
  Male                        322 (53.8)           288 (55.1)           0.660         73 (48.0)                                  137 (60.9)                            78 (53.4)         **0.043**     60 (60.6)         228 (53.8)        0.218
  Female                      277 (46.2)           235 (44.9)                         79 (52.0)                                  88 (39.1)                             68 (46.6)                       39 (39.4)         196 (46.2)        
  Age                         63.94 ± 10.05        63.13 ± 9.51         0.388         63.48 ± 9.54                               62.94 ± 9.70                          63.07 ± 9.21      0.893         50.61 ± 8.24      66.06 ± 7.11      **\<0.001**
  Age at onset                NA                   58.42 ± 9.76         NA            59.20 ± 9.77                               58.45 ± 9.93                          57.78 ± 9.48      0.670         44.06 ± 5.82      61.85 ± 7.05      **\<0.001**
  Disease duration (year)     NA                   4.52 ± 4.29          NA            3.51 ± 3.87                                4.66 ± 4.63                           5.36 ± 3.96       **\<0.001**   6.32 ± 6.20       4.10 ± 3.59       **0.003**
  Hoehn and Yahr stage                                                                                                                                                                                                                     
  1--1.5                      NA                   233 (46.8)           NA            78 (52.0)                                  101 (48.6)                            54 (38.6)         **0.025**     38 (40.8)         195 (48.1)        0.248
  2--2.5                      NA                   193 (38.7)                         60 (40.0)                                  75 (36.1)                             58 (41.4)                       37 (39.8)         156 (38.6)        
  ≥ 3                         NA                   72 (14.5)                          12 (8.0)                                   32 (15.4)                             28 (20.0)                       18 (19.4)         54 (13.3)         
  Oral LED/day (mg)           NA                   366.64 ± 287.7       NA            263.61 ± 234.14                            397.34 ± 299.85                       423.87 ± 292.24   **\<0.001**   424.46 ± 333.15   352.58 ± 274.23   0.104
  Smokers (Yes/No)            163/436              74/449               **\<0.001**   20/132                                     42/183                                12/134            **0.017**     19/80             55/369            0.110
  Alcohol drinkers (Yes/No)   102/497              62/461               **0.014**     14/138                                     35/190                                13/133            0.075         12/87             50/374            0.927

TD, tremor dominant subtype of Parkinson's disease; AR, Akinetic/Rigid dominant subtype of Parkinson's disease; MX, mixed subtype of Parkinson's disease; EOPD, early onset Parkinson's disease; LOPD, late onset Parkinson's disease; SD, standard deviation; NA, not available.

P

-values that reach statistical significance were shown in bold.

a

Attributes data are presented as mean ± SD; variables data are presented as numbers (%).

Lack of Association Between DJ-1 Promoter Polymorphisms and PD in Single-Point Analysis
---------------------------------------------------------------------------------------

Three single nucleotide polymorphisms (SNPs) and one 18 bp deletion were observed in our cohort. Each of them already has a reference in the SNP database of NCBI (rs17523802, rs226249, rs200968609, and rs35675666). Schematic view of relative positions of these polymorphisms according to TSS was shown in [Figure 1](#F1){ref-type="fig"}. All the four variations were in HWE among PD and controls (*P* \> 0.001). There was no statistical difference in genotype or allele distribution of the four variations between the entire PD group and control ([Table 2](#T2){ref-type="table"}). When patients were stratified by life style factors (cigarette or alcohol intake), no significance of allele or genotype distribution was observed in all subgroups for the four variations (data not shown). Stratification analysis of age or gender also showed no statistical differences between PD and control among the four variations after Bonferroni adjustment (data not shown).

###### 

Genotype and allele distribution between total PD patients and controls of polymorphisms in DJ-1 promoter region.

  SNP ID^a^     Position^b^   Allele/Genotype   PD (*n* = 523)   Control (*n* = 599)   *p^c^*   OR (95% CI)^c^
  ------------- ------------- ----------------- ---------------- --------------------- -------- ---------------------
  Rs17523802    --21          G                 982 (93.9)       1107 (92.4)           0.221    0.806 (0.570,1.139)
                              A                 64 (6.1)         91 (7.6)                       
                              GG                460 (87.9)       510 (85.2)            0.215    0.800 (0.562,1.139)
                              GA                62 (11.9)        87 (14.5)                      
                              AA                1 (0.2)          2 (0.3)                        
  Rs226249      18            C                 681 (65.1)       802 (66.9)            0.123    1.155 (0.962,1.386)
                              T                 365 (34.9)       396 (33.1)                     
                              CC                232 (44.4)       274 (45.7)            0.131    1.147 (0.96,1.369)
                              CT                217 (41.5)       254 (42.4)                     
                              TT                74 (14.1)        71 (11.9)                      
  Rs200968609   168_185del    Ins               982 (93.9)       1107 (92.4)           0.221    0.806 (0.570,1.139)
                              Del               64 (6.1)         91 (7.6)                       
                              Ins/ins           460 (87.9)       510 (85.2)            0.215    0.800 (0.562,1.139)
                              Ins/del           62 (11.9)        87 (14.5)                      
                              Del/del           1 (0.2)          2 (0.3)                        
  Rs35675666    213           G                 982 (93.9)       1107 (92.4)           0.221    0.806 (0.570,1.139)
                              T                 64 (6.1)         91 (7.6)                       
                              GG                460 (87.9)       510 (85.2)            0.215    0.800 (0.562,1.139)
                              GT                62 (11.9)        87 (14.5)                      
                              TT                1 (0.2)          2 (0.3)                        

OR, odds ratio; 95% CI, 95% confidence interval.

a

SNP ID represents the ID of each polymorphism recorded in the NCBI SNP database.

b

The first base of TSS was defined as 1, the first upstream base of TSS is -1, the relative position of each polymorphism was calculated based on TSS.

c

Adjusted for age, gender, cigarettes, and alcohol.

To investigate the association between polymorphisms and PD clinical phenotypes, genotype and allele distribution analysis between control and clinical subtypes of PD were further conducted. However, no significant difference was reached on either the genotype or allele distribution of the four variations among the entire control group and the motor subtypes of PD or among the EOPD (age of onset \< 50), LOPD (age of onset ≥ 50) group and control group ([Table 3](#T3){ref-type="table"}).

###### 

Allele distribution of DJ-1 promoter polymorphisms between controls and different PD subtypes classified by motor features or age at onset.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP ID        Allele/\                 Motor subtype of PD   AR vs. TD    Onset-age PD subtypes   EOPD vs. LOPD                                                        
                genotype                                                                                                                                                 
  ------------- ---------- ------------- --------------------- ------------ ----------------------- --------------- ------------------ ------------ ------------ ------- ------------------
  rs17523802    G          1107 (92.4)   277 (91.1)            420 (93.3)   277 (94.9)              0.312           0.75 (0.44,1.3)    186 (93.9)   794 (93.9)   0.221   0.81 (0.57,1.14)

                A          91 (7.6)      27 (8.9)              30 (6.7)     15 (5.1)                                                   12 (6.1)     52 (6.1)             

                GG         510 (85.2)    125 (82.2)            196 (87.1)   131 (89.7)              0.299           0.74 (0.42,1.3)    87 (87.9)    373 (88.0)   0.457   0.67 (0.24,1.92)

                GA         87 (14.5)     27 (17.8)             28 (12.4)    15 (10.3)                                                  12 (12.1)    50 (11.8)            

                AA         2 (0.3)       0 (0)                 1 (0.4)      0 (0)                                                      0 (0)        1 (0.2)              

  rs226249      C          802 (66.9)    200 (65.8)            285 (63.3)   196 (67.1)              0.525           1.11 (0.81,1.51)   136 (68.7)   544 (64.3)   0.12    1.16 (0.96,1.39)

                T          396 (33.1)    104 (34.2)            165 (36.7)   96 (32.9)                                                  62 (31.3)    302 (35.7)           

                CC         274 (45.7)    64 (42.1)             99 (44)      69 (47.3)               0.540           1.10 (0.82,1.48)   50 (50.5)    182 (42.9)   0.88    1.04 (0.65,1.66)

                CT         254 (42.4)    72 (47.4)             87 (38.7)    58 (39.7)                                                  36 (36.4)    181 (42.7)           

                TT         71 (11.9)     16 (10.5)             39 (17.3)    19 (13)                                                    13 (13.1)    61 (14.4)            

  rs200968609   Ins        1107 (92.4)   277 (91.1)            420 (93.3)   277 (94.9)              0.312           0.75 (0.44,1.3)    186 (93.9)   794 (93.9)   0.221   0.81 (0.57,1.14)

                Del        91 (7.6)      27 (8.9)              30 (6.7)     15 (5.1)                                                   12 (6.1)     52 (6.1)             

                Ins/ins    510 (85.2)    125 (82.2)            196 (87.1)   131 (89.7)              0.299           0.74 (0.42,1.3)    87 (87.9)    373 (88.0)   0.45    0.67 (0.24,1.92)

                Ins/del    87 (14.5)     27 (17.8)             28 (12.4)    15 (10.3)                                                  12 (12.1)    50 (11.8)            

                Del/del    2 (0.3)       0 (0)                 1 (0.4)      0 (0)                                                      0 (0)        1 (0.2)              

  rs35675666    G          1107 (92.4)   277 (91.1)            420 (93.3)   277 (94.9)              0.312           0.75 (0.44,1.3)    186 (93.9)   794 (93.9)   0.22    0.81 (0.57,1.13)

                T          91 (7.6)      27 (8.9)              30 (6.7)     15 (5.1)                                                   12 (6.1)     52 (6.1)             

                GG         510 (85.2)    125 (82.2)            196 (87.1)   131 (89.7)              0.299           0.74 (0.42,1.3)    87 (87.9)    373 (88.0)   0.46    0.67 (0.24,1.92)

                GT         87 (14.5)     27 (17.8)             28 (12.4)    15 (10.3)                                                  12 (12.1)    50 (11.8)            

                TT         2 (0.3)       0 (0)                 1 (0.4)      0 (0)                                                      0 (0)        1 (0.2)              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TD, tremor dominant subtype of Parkinson's disease; AR, Akinetic/Rigid dominant subtype of Parkinson's disease; MX, mixed subtype of Parkinson's disease; EOPD, early onset Parkinson's disease; LOPD, late onset Parkinson's disease.

a

Adjusted for age, gender, cigarettes and alcohol.

Lack of Association Between DJ-1 Promoter Polymorphisms and PD in Haplotype Analysis
------------------------------------------------------------------------------------

Since the four detected polymorphisms were located on the same chromosome, to explore whether they were in linkage disequilibrium (LD) linkage analysis was performed. Strong linkage patterns were observed among rs17523802, rs200968609, and rs35675666) (*r*^2^ = 1.0, D' = 1.0, LOD = 206.52). The four variations constitute one block of haplotype. Three Haplotypes with a frequency greater than 1% in all samples (G-T-ins-G, G-C-ins-G, and A-C-del-T, alleles arrayed in order of rs17523802, rs226249, rs200968609, and rs35675666) were selected to analyze. However, the frequency of the three Haplotypes showed no difference between PD and control ([Table 4](#T4){ref-type="table"}).

###### 

Haplotype frequencies of the four variations in DJ-1 promoter region.

            Haplotype^a^    Total         PD           control      *p*     OR (95% CI)
  --------- --------------- ------------- ------------ ------------ ------- -------------------
                            2N = 2244     2n = 1046    2n = 1198            
  Block 1   1\. G-C-ins-G   1320 (58.8)   609 (58.2)   711 (59.3)   0.588   0.96 (0.81, 1.13)
            2\. G-T-ins-G   761 (33.9)    365 (34.9)   396 (33.1)   0.358   1.09 (0.91, 1.29)
            3\. A-C-del-T   163 (7.3)     72 (6.9)     91 (7.6)     0.516   0.90 (0.65, 1.24)

OR, odds ratio; 95% CI, 95% confidence interval.

a

Alleles in haplotype are arrayed in order of rs17523802, rs226249, rs200968609, and rs35675666.

Analyzing Effects of the Four Variations on PD With Public GWAS Database
------------------------------------------------------------------------

To further evaluate the effect of these polymorphisms on PD, we looked up these polymorphisms in existing public genomic databases. As shown in [Table 5](#T5){ref-type="table"}, MAF of the four variations in our study were quite in accordance with the MAFs of East Asian population in 1000 Genome Project database, and lower than the MAFs of all population in either 1000 Genome Project database or TOPMED program database. We searched the meta-analysis results based on 13,708 PD cases and 95,282 controls from 13 independent GWAS datasets of European descent in PDGene database. Due to data sharing restrictions, detailed genotype information of the four variations were not accessible. Thus, only Meta *p* values and Meta OR of the four variations in GWAS reports were listed in [Table 5](#T5){ref-type="table"}. All the four variations showed Meta *P*-value \> 0.05, which suggested, not only in Chinese as this study observed, the four variations may also not be associated with PD in European populations.

###### 

The frequencies of polymorphisms detected in present study and in public databases.

  Polymorphisms   Minor allele frequency (%)                                                         
  --------------- ---------------------------- ------ ------------- ------- ---- ------- ----------- --------
  --21 G \> A     6.1                          7.6    rs17523802    17.65   7    22.33   \>0.05      \>1
  18 C \> T       34.9                         33.1   rs226249      36.26   33   29.18   \>0.05^§^   \>1^§^
  168_185del      6.1                          7.6    rs200968609   9.29    7    --      \>0.05^§^   \>1^§^
  213 G \> T      6.1                          7.6    rs35675666    14.82   7    18.36   \>0.05      \>1

TOPMED, Trans-Omics for Precision Medicine Program.

a

The meta-analysis includes data up to 13,708 PD cases and 95,282 control from 15 independent GWAS datasets. The meta

p

-value ≥ 0.05 corresponds to

p

-values ≤ 1 and ≥0.05.

§

rs226249 and rs200968609 had no record in the database; Since rs226249 was in LD with rs2493215 (

r

2

= 0.896 in 1000 Genome), we looked up rs2493215 to represent rs226249 in PDGene and found a Meta

p

-value \> 0.05 with Meta OR \> 1; considering rs200968609 was in LD with rs17523802 and rs35675666 (

r

2

= 0.896 in 1000 Genome), the results of rs17523802 and rs35675666 could also represent that of rs200968609.

Meta-Analysis of DJ-1 Promoter Polymorphisms Based on This Study and Other Previous Reports
-------------------------------------------------------------------------------------------

Except for meta-analysis on GWAS reports, a meta-analysis of the four variations with PD was performed based on this study and other related previous case-control studies ([@B8]; [@B16]; [@B6]; [@B21]; [@B22]; [@B10]). Detailed information of previous studies was shown in [Table 6](#T6){ref-type="table"}. Consistent with our results, no significant associations were observed between these polymorphisms and PD (rs17523902 *p* = 0.777, rs226249 *p* = 0.816, rs200968609 *p* = 0.188, and rs35675666 *p* = 0.276) at the allelic level under the random effect model ([Figure 2](#F2){ref-type="fig"}), which indicated that DJ-1 promoter polymorphisms may play little role in PD susceptibility in different ethnic populations.

###### 

Detailed information of previous studies selected into meta-analysis.

                                            PD     Control                                                     
  ------------- --- --------- ------------- ------ ---------------- ------ ----- ------------ ---------------- --------
  --21 G \> A   1   7961680   rs17523802    2.5    163EOPD          6      100   0.039^a^     Italian          [@B22]
                                            21.4   138PD            10.5   38    0.033^§^     Indian           [@B21]
                                            12.2   294PD            7.3    298   0.005        Italian          [@B6]
  18 C \> T     1   7961718   rs226249      44.5   163EOPD          44     100   0.915^a^     Italian          [@B22]
                                            56.2   138PD            67.1   38    0.086^§^     Indian           [@B21]
  168_185del    1   7961913   rs200968609   8.9    163EOPD          10.5   100   0.543^a^     Italian          [@B22]
                                            31     136sporadic PD   29     129   0.65         Finnish          [@B8]
                                            11     308PD            8.7    248   0.19^§^      Indian           [@B21]
                                            23     46PD             18     96    0.362^§^     England          [@B16]
                                            13.8   294PD            6.9    298   \<0.001      Italian          [@B6]
                                            0.2    285PD            0      264   0.497        White            [@B10]
                                            1      99PD             1.1    132   0.337        Mixed ancestry   [@B10]
                                            5.6    18PD             1.1    132   0.111        Black African    [@B10]
  213 G \> T    1   7961850   rs35675666    2.5    163EOPD          0.5    100   0.193^a^     Italian          [@B22]
                                            22.1   86PD             5.1    39    \<0.001^§^   Indian           [@B21]

Chr, chromosome; pos (hg38), SNP position on hg38 reference sequence; MAF, minor allele frequency.

a

Values were non-significant according to Bonferroni correction (

p

\< 0.002).

§

P

values calculated with provided data in the studies (which were not directly provided in the studies).

![Forest plots of the meta-analysis between DJ-1 promoter polymorphisms and PD under the allelic model. For meta-analysis, rs17523902 *p* = 0.777, rs226249 *p* = 0.816, rs200968609 *p* = 0.188, and rs35675666 *p* = 0.276. OR, odds ratio; CI, confidence interval; I-squared, heterogeneity.](fnagi-11-00024-g002){#F2}

Effects of Promoter Polymorphisms on DJ-1 Promoter Transcriptional Activity
---------------------------------------------------------------------------

To test whether the four variations alter DJ-1 promoter transcriptional activity, dual-luciferase reporter gene assay was conducted. As shown in [Figure 3](#F3){ref-type="fig"}, allele alteration of rs226249 or rs17523802/rs200968609/rs35675666 had no effect on DJ-1 promoter transcriptional activity.

![The influence of promoter polymorphisms on DJ-1 promoter transcriptional activity. Dual-luciferase reporter assay was used to access whether rs226249 **(A)** or rs17523802/rs200968609/rs35675666 **(B)** affect DJ-1 promoter transcriptional activity. The haplotype alleles arrayed in order of rs17523802, rs226249, rs200968609, and rs35675666. The data were represented as mean ± SE from four independent transfection experiments, each in duplicate.](fnagi-11-00024-g003){#F3}

EQTL (Expression Quantitative Trait Loci) Analysis of the Four Variations
-------------------------------------------------------------------------

To explore whether these DJ-1 promoter polymorphisms could impact human brain DJ-1 gene expression, eQTL analysis was conducted with data from dbGaP. As shown in [Figure 4](#F4){ref-type="fig"}, rs17523802 (*P* = 0.62), rs226249 (*P* = 0.8), and rs35675666 (*P* = 0.75) showed no association with DJ-1 gene expression in human brain substantia nigra. In addition, other brain regions including amygdala, anterior cingulate cortex (BA24), Caudate (basal ganglia), Frontal Cortex (BA9), Hippocampus, Hypothalamus, nucleus accumbens (basal ganglia), putamen (basal ganglia), spinal cord (cervical c-1) were also analyzed and found negative results ([Table 7](#T7){ref-type="table"}).

![Effect of rs17523802 **(A)**, rs226249 **(B)**, rs356756666 **(C)** genotype on DJ-1 mRNA expression in normal human brain substantia nigra. Data of rs200968609 were not found in dbGap.](fnagi-11-00024-g004){#F4}

###### 

Effect of rs17523802, rs226249, and rs356756666 on DJ-1 mRNA expression in different regions of normal human brain.

  Polymorphisms   Gene    dbSNP number   Tissue                                     *P*-value   Effect size
  --------------- ------- -------------- ------------------------------------------ ----------- -------------
  --21 G \> A     PARK7   rs17523802     Brain--Amygdala                            0.19        --0.1
                                         Brain--Anterior cingulate cortex (BA24)    0.23        --0.089
                                         Brain--Caudate (basal ganglia)             0.81        --0.016
                                         Brain--Frontal Cortex (BA9)                0.18        --0.084
                                         Brain--Hippocampus                         0.097       --0.092
                                         Brain--Hypothalamus                        0.065       --0.11
                                         Brain--Nucleus accumbens (basal ganglia)   0.4         --0.052
                                         Brain--Putamen (basal ganglia)             0.55        0.047
                                         Brain--Spinal cord (cervical c-1)          0.38        0.066
                                         Brain--Substantia nigra                    0.62        0.045
  18 C \> T       PARK7   rs226249       Brain--Amygdala                            0.48        0.043
                                         Brain--Anterior cingulate cortex (BA24)    0.84        0.013
                                         Brain--Caudate (basal ganglia)             0.26        --0.06
                                         Brain--Frontal Cortex (BA9)                0.22        0.071
                                         Brain--Hippocampus                         0.35        --0.044
                                         Brain--Hypothalamus                        0.38        0.049
                                         Brain--Nucleus accumbens (basal ganglia)   0.51        0.032
                                         Brain--Putamen (basal ganglia)             0.33        --0.058
                                         Brain--Spinal cord (cervical c-1)          0.68        0.027
                                         Brain--Substantia nigra                    0.8         --0.017
  213 G \> T      PARK7   rs35675666     Brain--Amygdala                            0.27        --0.089
                                         Brain--Anterior cingulate cortex (BA24)    0.24        --0.087
                                         Brain--Caudate (basal ganglia)             0.64        --0.032
                                         Brain--Frontal Cortex (BA9)                0.11        --0.099
                                         Brain--Hippocampus                         0.2         --0.072
                                         Brain--Hypothalamus                        0.073       --0.11
                                         Brain--Nucleus accumbens (basal ganglia)   0.46        --0.046
                                         Brain--Putamen (basal ganglia)             0.61        0.041
                                         Brain--Spinal cord (cervical c-1)          0.4         0.064
                                         Brain--Substantia nigra                    0.75        0.029

Discussion
==========

The antioxidative effect of DJ-1 plays an important role in cell survival, deficiency or low level of DJ-1 protein makes neurons more susceptible to oxidative stress and result in the occurrence of PD. In familial PD, such deficiency is caused by mutations in DJ-1 gene, whereas in sporadic PD, who lacks mutations in DJ-1, the reason of a low brain DJ-1 protein level remains obscure. This study attempted to reveal whether polymorphisms in DJ-1 promoter were associated with PD through affecting the regulation of DJ-1 expression. In the present study, we sequenced the core region of DJ-1 promoter in 523 sporadic PD patients and 599 controls in Chinese Han population of mainland, and finally found four variations (rs17523802, rs226249, rs200968609, and rs35675666). However, no significant association was found between all the four detected polymorphisms and the risk of PD either in the allelic model or genotype model, in single-point analysis or haplotype analysis. After stratification by age, gender, PD subtypes or habitude of cigarette or alcohol, we still failed to find any difference in the distribution of the four variations between PD and control or among subtypes. Searching results in PDGene GWAS database and meta-analysis of the present study and previous reports also showed no association between the four variations and PD. In addition, eQTL analysis demonstrated lack of association between the four DJ-1 promoter polymorphisms and normal human brain DJ-1 gene expression. All of these results suggested DJ-1 promoter polymorphisms may play little role in regulating brain DJ-1 gene expression level and PD susceptibility.

To our best knowledge, this is the first survey of the association between DJ-1 promoter polymorphisms and PD risk in a relatively large sample size of Chinese sporadic PD patients. Previous reports on DJ-1 promoter polymorphisms are very rare, and the results are not consistent. [@B6] found rs17523802 (*P* = 0.005) and rs200968609 (*P* \< 0.001) were associated with PD risk in an Italian cohort (294PD and 298 control) ([Table 6](#T6){ref-type="table"}). Whereas, [@B21] suggested rs35675666 (*P* \< 0.001) was a risk factor of PD in an Indian population (86PD and 39 control), and rs17523802 and rs200968609 were not associated with PD ([Table 6](#T6){ref-type="table"}). Other studies ([@B8]; [@B16]; [@B22]; [@B10]) failed to find association between these polymorphisms and PD ([Table 6](#T6){ref-type="table"}). Meta-analysis of previous reports and our present study suggested no association between the four variations and PD. The results of GWAS database and eQTL analysis further confirmed that polymorphisms in DJ-1 promoter region (rs17523802, rs226249, rs200968609, and rs35675666) were not associated with DJ-1 expression in human brain and the risk of PD.

Based on current findings, low DJ-1 protein level in sporadic PD patients is not a consequence of DJ-1 promoter polymorphisms. According to relevant researches, the low DJ-1 protein level in sporadic PD might be related to dysregulation of gene expression. On the transcriptional level, it might be caused by altered regulation of transcriptional factors or epigenetic regulation such as DNA methylation and histone modifications. [@B25] and [@B7], respectively, found the transcription factor SP-1 ([@B25]) or XBP-1S ([@B7]) could bind to the DJ-1 promoter region and increase its transcriptional activity, suggesting that expression or activity alterations of transcriptional factors might be associated with PD. [@B31] demonstrated that deacetylase inhibitors such as phenyl butyrate and sodium butyrate could increase DJ-1 mRNA and protein expression to protect cells against oxidative stress, which suggested alterations of acetylation of histone for DJ-1, might affect DJ-1 expression. However, in our previous study ([@B26]), we found that DNA methylation did not regulate DJ-1 expression. On the post-transcriptional level, microRNAs may have an effect on the expression of DJ-1 protein level. Our previous study ([@B4]) found that MircoRNA-4639 could downregulate DJ-1 expression and had the potential to be a biomarker for PD. Thus, low DJ-1 protein levels in sporadic PD might be a combination result of a variety of factors, future studies on detailed mechanisms would be needed.

In conclusion, our results implicated that DJ-1 promoter polymorphisms may not be associated with PD risk.
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